• 1
    Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588.
  • 2
    Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101.
  • 3
    Wright TC, Schiffman M, Solomon D, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004; 103: 304-309.
  • 4
    Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
  • 5
    Munoz N, Bosch FX, Sanjose SD, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348: 518-527.
  • 6
    Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197: 340-345.
  • 7
    Wright TC Jr, Massad LS, Dunton CJ, et al. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346-355.
  • 8
    Solomon D, Schiffman M, Tarone R. Comparison of 3 management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst. 2001; 93: 293-299.
  • 9
    Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003; 88: 63-73.
  • 10
    Schiffman M, Castle PE, Jernimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890-907.
  • 11
    Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 1072-1079.
  • 12
    Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005; 97: 1099-1071.
  • 13
    Wheeler CM, Hunt WC, Schiffman M, et al. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006; 194: 1291-1299.
  • 14
    Naucler P, Ryd W, Tornberg S, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer. 2007; 97: 129-132.
  • 15
    Evans MF, Adamson CS, Papillo JL, St. John TL, Leiman G, Cooper K. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes. Cancer. 2006; 106: 1054-1064.
  • 16
    Wong AK, Chan RC, Nichols WS, Bose S. Human papillomavirus (HPV) in atypical squamous cervical cytology: the Invader HPV test as a new screening assay. J Clin Micro. 2008; 46: 869-875.
  • 17
    Ginoccio CC, Barth D, Zhang F. Comparison of the Third Wave Invader human papillomavirus (HPV) assay and the Digene HPV Hybrid Capture 2 Assay for the detection of high-risk human papillomavirus DNA. J Clin Micro. 2008; 46: 1641-1646.
  • 18
    Davey DD, Neal MH, Wilbur DC, Colgan TJ, Styer PE, Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004; 128: 1224-1229.
  • 19
    Gravitt PE, Peyton CL, Apple RJ, Wheeler CM. Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol. 1998; 36: 3020-3027.
  • 20
    Quantitative Skills Consultancy for Research and Statistics. Simple Interactive Biostatistical Analysis. Biostatistics tools. Available at: Accessed June 1, 2008.
  • 21
    Castle PE. The potential utility of HPV genotyping in screening and clinical management. J Natl Compr Canc Netw. 2008; 6: 83-95.
  • 22
    Guo M, Lin CY, Gong Y, et al. Human papillomavirus genotyping for the 8 oncogenic types can improve specificity of HPV testing in women with mildly abnormal Pap results. Mod Pathol. 2008; 21: 1037-1043.
  • 23
    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin number 66, September 2005: management of abnormal cervical cytology and histology. Obstet Gynecol. 2005; 106: 645-664.
  • 24
    Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson GJ. 2001 Consensus guidelines for the management of women with cervical cytological abnormalities. JAMA. 2002; 287: 2120-2129.